Anticholinergic and sedative medications exposure in older patients: a cross-sectional study

被引:7
|
作者
Zhang, Xiaolin [1 ]
Zhou, Shuang [2 ]
Li, Xinran [2 ]
Zhou, Weiwei [1 ]
Zhou, Ying [2 ]
Cui, Yimin [2 ]
Liu, Xinmin [1 ]
机构
[1] Peking Univ, Dept Geriatr, Hosp 1, Beijing, Peoples R China
[2] Peking Univ, Dept Pharm, Hosp 1, Beijing, Peoples R China
关键词
Anticholinergic effects; China; Drug Burden Index; Polypharmacy; Sedatives; DRUG BURDEN INDEX; POTENTIALLY INAPPROPRIATE MEDICATIONS; ADULTS; POLYPHARMACY; CRITERIA; PRESCRIPTIONS; ASSOCIATION; OUTCOMES; PEOPLE; FALLS;
D O I
10.1007/s11096-019-00885-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background The Drug Burden Index is a risk assessment tool used to quantify anticholinergic and sedative medications burden of older patients. There have been no previously published reports the exposure of anticholinergic and sedative medications in China. Objective We investigated the prevalence and correlates risk factors of anticholinergic and sedative medications in hospitalized older patients with polypharmacy in China. Settings The Department of Geriatrics in a tertiary care teaching hospital. Methods A retrospective analysis of patient medical records of hospitalized older patients with polypharmacy was undertaken at a large university teaching hospital in China. Polypharmacy was defined as the regular use of more than five medications. Prescribing of anticholinergic and sedative medications was identified using the medication list of the Drug Burden Index, and logistic regression analysis determined associations between drug exposure and independent variables. Main outcome measure Anticholinergic and sedative medications identified by the Drug Burden Index. Results A total of 383 patients were included in this study, with an average age of 82.6 +/- 7.0 years and included 72.9% (279/383) male patients. Of the study participants, 23.8% (91/383) were prescribed anticholinergic and sedative medications. Of the 106 medicines identified by the Drug Burden Index, the most frequently prescribed medications were estazolam in 51.9% (55/106), terazosin in 14.1% (15/106), loratadine in 10.4% (11/106), and cetirizine in 5.7% (6/106); these four medications accounted for 82.1% of the anticholinergic and sedative medications. Drug exposure was associated with age >= 80 years (OR 2.246; 95% CI 1.100-4.586), the number of prescribed medications (OR 1.102; 95% CI 1.018-1.193), and symptoms of insomnia (OR 28.990; 95% CI 14.197-59.200). Conclusions The findings of this study showed that the prevalence of anticholinergic and sedative exposure in hospitalized older patients with polypharmacy in China. The prevalence of exposure of anticholinergic and sedative medications was 23.8%. According to the Drug Burden Index estazolam and terazosin were the most common medications in the sedative or anticholinergic drug class, respectively.
引用
收藏
页码:1152 / 1158
页数:7
相关论文
共 50 条
  • [21] Association of anticholinergic burden with adverse effects in older people with intellectual disabilities: an observational cross-sectional study
    O'Dwyer, Maire
    Maidment, Ian D.
    Bennett, Kathleen
    Peklar, Jure
    Mulryan, Niamh
    McCallion, Philip
    McCarron, Mary
    Henman, Martin C.
    BRITISH JOURNAL OF PSYCHIATRY, 2016, 209 (06) : 504 - 510
  • [22] Influence of chronic medical conditions on older patients' willingness to deprescribe medications: a cross-sectional study
    Pereira, Anabela
    Verissimo, Manuel
    Ribeiro, Oscar
    BMC GERIATRICS, 2024, 24 (01)
  • [23] Potentially inappropriate medications and polypharmacy in the older population: A nationwide cross-sectional study in France in 2019
    Drusch, Solene
    Zureik, Mahmoud
    Herr, Marie
    THERAPIE, 2023, 78 (05): : 575 - 584
  • [24] Exposure to anticholinergic and sedative medications using the Drug Burden Index and its association with vertigo, dizziness and balance problems in older people - Results from the KORA-FF4 Study
    Phillips, Amanda
    Heier, Margit
    Strobl, Ralf
    Linkohr, Birgit
    Holle, Rolf
    Peters, Annette
    Grill, Eva
    EXPERIMENTAL GERONTOLOGY, 2019, 124
  • [25] Analysis of anticholinergic and sedative medicine effects on physical function, cognitive function, appetite and frailty: a cross-sectional study in Australia
    Lim, Renly
    Ellett, Lisa M. Kalisch
    Widagdo, Imaina S.
    Pratt, Nicole L.
    Roughead, Elizabeth Ellen
    BMJ OPEN, 2019, 9 (09):
  • [26] Disentangling drug contributions: anticholinergic burden in older adults linked to individual medications: a cross-sectional population-based study
    Gauri Bhatkhande
    Niteesh K. Choudhry
    Mufaddal Mahesri
    Nancy Haff
    Julie C. Lauffenburger
    BMC Geriatrics, 24
  • [27] Understanding older patients' willingness to have medications deprescribed in primary care: a protocol for a cross-sectional survey study in nine European countries
    Luethold, Renata Vidonscky
    Jungo, Katharina Tabea
    Weir, Kristie Rebecca
    Geier, Anne-Kathrin
    Scholtes, Beatrice
    Kurpas, Donata
    Wild, Dorothea M. G.
    Petrazzuoli, Ferdinando
    Thulesius, Hans
    Lingner, Heidrun
    Assenova, Radost
    Poortvliet, Rosalinde K. E.
    Lazic, Vanja
    Rozsnyai, Zsofia
    Streit, Sven
    BMC GERIATRICS, 2022, 22 (01)
  • [28] Prevalence and determinants of potentially inappropriate medication use in Hong Kong older patients: a cross-sectional study
    Zhang, Huanyu
    Wong, Eliza L. Y.
    Wong, Samuel Y. S.
    Chau, Patsy Y. K.
    Yip, Benjamin H. K.
    Chung, Roger Y. N.
    Lee, Eric K. P.
    Lai, Francisco T. T.
    Yeoh, Eng-Kiong
    BMJ OPEN, 2021, 11 (07):
  • [29] Association of anticholinergic burden with undernutrition in older adults: A cross-sectional study
    Naharci, Mehmet Ilkin
    Katipoglu, Bilal
    Tasci, Ilker
    NUTRITION IN CLINICAL PRACTICE, 2022, 37 (05) : 1215 - 1224
  • [30] Medications and the risk of falls among older people in a geriatric centre in Nigeria: a cross-sectional study
    Akande-Sholabi, Wuraola
    Ogundipe, Francis. S.
    Adebusoye, Lawrence. A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (01) : 236 - 245